Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial.
Lancet Oncol
; 24(3): 297-306, 2023 03.
Article
en En
| MEDLINE
| ID: mdl-36739879
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Isquemia Encefálica
/
Carcinoma Neuroendocrino
/
Accidente Cerebrovascular
/
Neutropenia
Tipo de estudio:
Clinical_trials
Límite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Lancet Oncol
Asunto de la revista:
NEOPLASIAS
Año:
2023
Tipo del documento:
Article